179 related articles for article (PubMed ID: 25287419)
1. Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study.
Collaco JM; Blackman SM; Raraigh KS; Morrow CB; Cutting GR; Paranjape SM
BMC Pulm Med; 2014 Oct; 14():159. PubMed ID: 25287419
[TBL] [Abstract][Full Text] [Related]
2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
3. Environmental allergies and respiratory morbidities in cystic fibrosis.
Collaco JM; Morrow CB; Green DM; Cutting GR; Mogayzel PJ
Pediatr Pulmonol; 2013 Sep; 48(9):857-64. PubMed ID: 23143815
[TBL] [Abstract][Full Text] [Related]
4. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
[TBL] [Abstract][Full Text] [Related]
5. CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.
Radtke T; Hebestreit H; Gallati S; Schneiderman JE; Braun J; Stevens D; Hulzebos EH; Takken T; Boas SR; Urquhart DS; Lands LC; Tejero S; Sovtic A; Dwyer T; Petrovic M; Harris RA; Karila C; Savi D; Usemann J; Mei-Zahav M; Hatziagorou E; Ratjen F; Kriemler S;
Ann Am Thorac Soc; 2018 Feb; 15(2):209-216. PubMed ID: 29140739
[TBL] [Abstract][Full Text] [Related]
6. Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
Welsh L; Robertson CF; Ranganathan SC
Pediatr Pulmonol; 2014 Sep; 49(9):873-7. PubMed ID: 24178906
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
[TBL] [Abstract][Full Text] [Related]
9. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.
Collaco JM; Vanscoy L; Bremer L; McDougal K; Blackman SM; Bowers A; Naughton K; Jennings J; Ellen J; Cutting GR
JAMA; 2008 Jan; 299(4):417-24. PubMed ID: 18230779
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.
McGarry ME; Neuhaus JM; Nielson DW; Burchard E; Ly NP
Pediatr Pulmonol; 2017 Dec; 52(12):1550-1557. PubMed ID: 29082671
[TBL] [Abstract][Full Text] [Related]
11. Variation in lung function and nutritional decline in cystic fibrosis by genotype: An analysis of the Canadian cystic fibrosis registry.
Leung GJ; Cho TJ; Kovesi T; Hamid JS; Radhakrishnan D
J Cyst Fibros; 2020 Mar; 19(2):255-261. PubMed ID: 31253541
[TBL] [Abstract][Full Text] [Related]
12. Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation.
Keller BM; Aebischer CC; Kraemer R; Schöni MH
J Cyst Fibros; 2003 Jun; 2(2):76-83. PubMed ID: 15463854
[TBL] [Abstract][Full Text] [Related]
13. Clinical expression of cystic fibrosis in a large cohort of Italian siblings.
Terlizzi V; Lucarelli M; Salvatore D; Angioni A; Bisogno A; Braggion C; Buzzetti R; Carnovale V; Casciaro R; Castaldo G; Cirilli N; Collura M; Colombo C; Di Lullo AM; Elce A; Lucidi V; Madarena E; Padoan R; Quattrucci S; Raia V; Seia M; Termini L; Zarrilli F
BMC Pulm Med; 2018 Dec; 18(1):196. PubMed ID: 30577776
[TBL] [Abstract][Full Text] [Related]
14. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
15. Genetic modifiers of nutritional status in cystic fibrosis.
Bradley GM; Blackman SM; Watson CP; Doshi VK; Cutting GR
Am J Clin Nutr; 2012 Dec; 96(6):1299-308. PubMed ID: 23134884
[TBL] [Abstract][Full Text] [Related]
16. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.
Keating CL; Liu X; Dimango EA
Chest; 2010 May; 137(5):1157-63. PubMed ID: 19965956
[TBL] [Abstract][Full Text] [Related]
17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.
Cogen J; Emerson J; Sanders DB; Ren C; Schechter MS; Gibson RL; Morgan W; Rosenfeld M;
Pediatr Pulmonol; 2015 Aug; 50(8):763-70. PubMed ID: 26061914
[TBL] [Abstract][Full Text] [Related]
19. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
[TBL] [Abstract][Full Text] [Related]
20. [Italian Cystic Fibrosis Register - Report 2010].
Amato A; Ferrigno L; Salvatore M; Toccaceli V;
Epidemiol Prev; 2016; 40(2 Suppl 2):1-47. PubMed ID: 27291389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
